Document:

Converted by EDGARwiz

English Translation

Product Manufacture and Purchase Agreement

Serial Number: CG-TA-160127

Party A: Guangdong Gewang Biotechnology Co., Ltd.

Party B: Taian Zhishengtang Ganoderma Co., Ltd.

Party C: Shandong Academy of Agricultural Sciences

Party B is a manufacturer specializing in the production of health products, and Party C is the owner of the “selenium-ganoderma capsule” formula. Party A and Party C signed a Licensing Agreement in accordance with the Contract Law of People’s Republic of China and related laws and regulations, which exclusively permits Party A to use the “selenium-ganoderma capsule” formula. According to the above agreement content, after approved by Party C, Party A cooperates with the manufacturer designated by Party C, namely Party B, hence Party A and Party B reach consensus with respect to the relevant matters of production and purchase of selenium- ganoderma capsule and sign the following agreement terms to abide by.

I. Cooperation Contents

Party B produces products according to the formula provided by Party A, and Party A labels its owned registered trademark to the product. Party A shall supervise Party B’s entire production process with an appointed staff. Party A purchases products from Party B through purchasing order (see appendix) and pays the purchase expenses.

II. Cooperation Term

The cooperation term between Party A and Party B is five years and shall be effective as of the date of signing of this contract.

III. Time of Delivery and Method of Transportation

Party B shall arrange delivery within 20 days after receiving the purchasing order (in 

duplicate). Party A selects method of transportation and bears the freight and delivers the goods to the agreed address in the purchasing order.

IV. Confirmation of Receipt

Party B shall send the invoice and signed purchasing order with delivery date and to Party A for confirmation after delivering according to agreement.

V. Payment for Goods and Settlement

Party A shall pay in full within 20 days after receiving the invoice and purchasing order that Party B sent (when there is holidays the time shall be postponed). The product’s unit price and full amount is subject to the arrangement of the purchasing order.

       

VI. Rights and Obligations of Party A

1. Party A has the right to require Party B to provide the valid qualifications and certifications needed for producing health care products.

2. Party A has the right to require Party B to label Party A’s registered trademark on the products produced by Party B.

3. Party A has the right to arrange personnel to Party B’s production base for the supervision of production.

4. Party A shall settle the payment for Party B on schedule strictly upon stipulations of the agreement, and Party A shall undertake the corresponding responsibilities for breaching the contract if Party A does not perform the obligations according to the agreement.

VII. Duties and Obligations of Party B

1. Party B shall deliver the goods to the designated place as appointed.

2. Party B shall print Party A’s registered trademarks on the products provided for Party A.

3. Party B shall ensure that the product packaging conforms to the national regulations and ensure the security of transportation of products.

4. Party B shall accept the technical guidance and production supervision of the professionals of Party A.

5. The products provided by Party B shall conform to the quality requirements agreed by two parties and ensure the conformance to the state or local food hygienic standard. 

6. Party B has the confidential obligation to the formulas obtained.

VIII. Liability for Breach of Contract

1. After the signing of this agreement, both Parties shall comply with the principle of equality and sincerity and perform their own duties as agreed in the agreement. Any party who fail to perform this agreement or fail to meet the obligations stipulated in performing this agreement shall take liability for breach of contract and compensate all the actual losses therefore suffered by observant party.

2. Party B shall assume the liability of compensation for the economic losses of Party A due to products’ quality problem.

3. Party B shall change the goods in time and bear the cost for changing goods if the goods provided by Party B could not meet the standard agreed by both parties.

4. Should Party B delay the goods delivery without justified reasons, leading to Party A’s sales losses, the actual amount of which shall be borne by Party B.

5. During the cooperation period, any Party arbitrarily terminating the cooperation without any justified reasons shall be responsible for the actual loss therefore brought to the other party.

6. If Party B violates the confidentiality obligation stipulated herein, Party B shall be liable for breach of this agreement.

IX.Exception Clause

    

In the events that force majeure(such as flood,drought,disruption of railway and earthquake) and other factors lead to failure of performance or failure of performance of obligations in a complete manner under this agreement, the Party who suffers from force majeure shall timely provide the corresponding evidence to the other Party. The agreement could be performed in an extended period, or partly performed, or not perform as per the resolution after common discussion (or judged by relevant competent authorities) by both Parties, meanwhile, the two Parties could be exempted from undertaking the whole or part responsibilities for breach of contract pursuant to actual circumstances.

X. Disputes Settlement

In the event that any disputes arising in the process of performing the agreement, both Parties shall negotiate with each other based on the principles of long-term cooperation and jointly seeking for development; if it fails, both Parties could apply for conciliation; if it fails, too, either Party is entitled to file a suit to a People’s Court where Party A locates.

XI. Termination and Discharge of the Contract

1. The agreement would automatically terminate when it expires, except the situation that both parties agree to extend in writing.

2. If one party violates any terms of the contract, the other party has the right to terminate this contract.

3. If one party suffered from bankruptcy, liquidation, dissolution or being listed as dishonored account by the bank, the other party has the right to terminate this contract.

XII.Miscellaneous

1. The contract shall be effective as of the date of signing and seal by both parties. The contract is made in duplicates and each party holds one counterpart with the same legal effect.

2. The contract shall not be changed without the mutual agreement of both parties; as for the matters not mentioned herein, a supplemental agreement could be signed by both parties as the supplement of the contract.

Party A: Guangdong Ge wang Biotechnology Co., Ltd. 

Signature and seal: Shili ZHANG

 

Party B: Taian Zhishengtang Ganoderma Co., Ltd. 

Signature and seal: 

Party C: Shandong Academy of Agricultural Sciences 

Signature and seal: Fu XU

Date: January 27, 2016

purchasing order 

Purchasing party:Guangdong Ge wang Biotechnology Shares Co., Ltd. (Party A)

Supplying party:Taian Zhishengtang Ganoderma Co., Ltd. (Party B)

In accordance with the agreement in Product Manufacture and Purchase Agreement(number:CG-YS-160127), Party B delivers its goods according to the agreement in this indent.

									
	The serial number of transaction

	Name

	Trademark

	Unit price

	Quantity

	Amount(yuan)

	Shipping address

	Contact person

	Contact number

	1

	 
	 
	 
	 
	 
	 
	 
	 

	2

	 
	 
	 
	 
	 
	 
	 
	 

	3

	 
	 
	 
	 
	 
	 
	 
	 

	5

	 
	 
	 
	 
	 
	 
	 
	 

	6

	 
	 
	 
	 
	 
	 
	 
	 

	Total:

	Date of purchasing order:

	Delivery time of Party B(signature and seal)Converted by EDGARwiz

English Translation

CHINA GEWANG BIOTECHNOLOGY, INC.

Private Offering of 10 Million Shares of Common Stock 

SUBSCRIPTION AGREEMENT

1.

SUBSCRIPTION. The undersigned subscriber (the “Subscriber”) hereby makes application to purchase the number of shares of common stock specified in Section 4 hereof (the “Shares”) to be issued by China Gewang Biotechnology, Inc. (the “Company”). The Purchase Price for the Shares will be 0.5 dollar per Share, as set forth in total in Section 4. The Purchase Price will be paid by wire transfer to the account of Guangdong Gewang Biotechnology Co., Ltd. the controlled affiliate of the Company, upon tender of this Agreement by the Subscriber.

2.

REPRESENTATIONS OF SUBSCRIBER. The Subscriber represents and warrants to the Company as follows:

(A)

The Subscriber has relied solely upon the information contained in (a) the Company’s Report on Form 8-K as of April 20, 2015, and (b) any information furnished in written form by the Company to the Subscriber and signed by the Company. The Subscriber is not relying upon any oral representations or other written information in making the decision to purchase the Shares subscribed for herein;

(B)

The Subscriber recognizes that the Shares have not been registered under the Securities Act of 1933, as amended (the -Act”) or under the securities laws of any state, and, therefore, cannot be resold unless the Shares are registered under the Act or unless an exemption from registration is available. The Subscriber further recognizes that no public agency has passed upon the accuracy or adequacy of any information presented by the Company in connection with this offering or the fairness of the terms of the offering;

(C)

The Subscriber is acquiring the Shares for his own account for long-term investment and not with a view toward resale, fractionalization or division, or distribution thereof;

(D)

The Subscriber (or its principals, if the Subscriber is an entity) has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of an investment in the Company and of making an informed investment decision, and does not require a Purchaser Representative;

(E)

The Subscriber is aware that the books and records of the Company will be available for inspection during this offering, upon reasonable notice, during reasonable business hours at the Company’s place of business;

(F)

The Subscriber has been provided access to any information he requested in evaluating his purchase of the Shares;

(G)

The Subscriber has been presented with the opportunity to ask questions and receive answers from officers of the Company relating to the terms and conditions of the offering and to obtain any additional information necessary to verify the accuracy of the information made available to the Subscriber; and

(H)

To the best of the Subscriber’s knowledge based upon appropriate diligence and investigation: (i) none of the cash or property that is paid or contributed to the Company by the Subscriber shall be derived from, or related to, any activity that is deemed criminal under United States law or that contravenes any federal, state, foreign or international laws and regulations dealing with money laundering; and (ii) no contribution or payment to the Company by the Subscriber comes from a source which would cause the Company to be in violation of the United States Bank Secrecy Act, the United States Money Laundering Control Act of 1986 or the United States International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001. The Subscriber also understands and agrees that the Company may release confidential information about the Subscriber (and, if the Subscriber is an entity, its record and beneficial owners) to government authorities, if the Company determines in its sole discretion that it is in the best interest of the Company to do so or that such release is required by applicable law.

3.

ACCREDITED INVESTOR. Please initial one of the following items:

A.

The undersigned Subscriber is an Accredited Investor (as defined by the Regulations of the Securities and Exchange Commission) because the undersigned:

is a natural person who has an individual net worth, or joint net worth with that person’s spouse, of more than $1,000,000 (the calculation of net worth not including, however, the Subscriber’s principal residence or any debt secured by same unless the debt exceeds the market value of the residence); or

is a natural person who had an individual income in excess of $200,000 (or $300,000 jointly with my spouse) in each of the two most recent years and who reasonably expects an income in excess of $200,000 (or $300,000 jointly with my spouse) in the current year; or

is an entity in which each of the equity owners is either (i) a natural person whose individual net worth, or joint net worth with that person’s spouse, is in excess of $1,000,000; or (ii) a natural person who has had individual income in excess of $200,000 or income with such person’s spouse in excess of $300,000 in each of the two most recent years and who reasonably expects individual income in excess of $200,000 or income with such person’s spouse in excess of $300,000 during the current year; or

is an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), a corporation, a Massachusetts or similar business trust, or a limited liability company, in each case not formed for the specific purpose of purchasing the Shares and with total assets in excess of $5,000,000.

B.

The undersigned is not an Accredited Investor.

(NOTE: Subscriptions will not be accepted from any person or entity that (which is not an Accredited Investor.)

4.

SHARES SUBSCRIBED FOR. The undersigned subscribes to purchase the following shares for the following Purchase Price:

I have read the document attached to this Subscription Agreement titled “Certain Risks of an Investment in the Company.” I understand that 1 may lose the money that I invest in the Shares, either because of the risks described in that document or for other reasons. 

5.

BINDING EFFECT. This Subscription Agreement is executed this 14 day of May, 2015, and shall bind the parties hereto and their respective heirs, executors, administrators, distributees, successors and assigns.

SUBSCRIBER: 

认购方:

Sign: 

袁建华

签名

Title: 

(if Subscriber is an entity)

职位

(如果认购方是一个实体)

Address:

Room 801. Unit 5. Building 5. Kuntie Qujing Power Supply Water-electricity Plant, Mahuangchong Village, (Min District, Qujing City, Yunnan Province 

地主:

云南省曲靖市麒麟去麻黄冲村昆铁曲靖供电水电所5幢5单元801室

ACCEPTED BY THE COMPANY THIS 14th DAY OF May, 2015

CHINA GEWANG BIOTECHNOLOGY, INC.

By: 袁建华

签名人:Jianhua Yuan

1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]